Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02157506
Other study ID # CXL-1427-02
Secondary ID CV013-006
Status Completed
Phase Phase 2
First received
Last updated
Start date June 30, 2014
Est. completion date July 31, 2015

Study information

Verified date July 2019
Source Bristol-Myers Squibb
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomized, double-blinded, placebo-controlled study of continuous 6-hour IV infusions of CXL-1427 in hospitalized patients with systolic heart failure.


Description:

This is a dose finding, randomized, double-blinded, placebo-controlled study of continuous 6-hour IV infusions of CXL-1427 in hospitalized patients with systolic heart failure which will first evaluate up to four ascending dose levels of CXL-1427 in up to four cohorts of 8 patients each (the "Dose Escalation" cohorts). Subsequently, up to three of the initial dose levels of CXL-1427 may be assessed in the additional "Expansion" cohorts of up to approximately 16 patients to gain further confidence in the results at these dose levels. The CXL-1427 dose that will be evaluated in the first cohort will be 3µg/kg/min. The dose levels for the next three sequential Dose Escalation cohorts will be dependent on clinical safety and tolerability, as well as the results of the invasive hemodynamic measurements.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date July 31, 2015
Est. primary completion date May 31, 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria:

- Inclusion Criteria -In order to be eligible for study participation, a patient MUST:

- Be = 18 and = 85 years of age;

- Have a left ventricular ejection fraction (LVEF) =40%, as assessed by echocardiography, a multigated acquisition (MUGA) scan or magnetic resonance imaging (MRI) within 3 months prior to or during the current hospitalization;

- Be hospitalized with a primary heart failure or heart failure-related reason, e.g., acute decompensation of heart failure, transplant evaluation, hemodynamic optimization prior to ambulatory inotropes or left ventricular assist device placement;

- Have an indwelling pulmonary artery (PA) catheter in place for assessment of central hemodynamic parameters; [Note: The indwelling catheter may already be in place for medically-indicated reasons, OR be placed for the primary purpose of monitoring the hemodynamic effects of the study drug. If the pulmonary artery catheter is to be placed for the sole purpose of monitoring the hemodynamic effect of the study drug, the patient must have a cardiac index (CI) = 2.2L/min•m2 as measured by a non-invasive cardiac output monitor (NICaS device) =6 hours prior to placement of the catheter. In this setting, Exclusion Criteria 3 below also applies.]

- Have a Fick and/or thermodilution determination of cardiac index =2.5L/min•m2 at screening, i.e., =4 hours before the intended start of the study drug infusion; [Note: For determinations of CI using the thermodilution method, a mean of three consecutive values measured approximately 5 minutes apart, none of which differs from the mean value by more than 15%, should be used.]

- Have a screening and baseline PCWP (or PAD, if a PCWP waveform cannot be reliably obtained) of =20 mmHg if systolic blood pressure is =100mmHg OR =22mmHg if systolic blood pressure is between 95-99mmHg (inclusive);

- Be considered sufficiently stable to be expected not to require administration of any IV or oral vasoactive medications, including diuretics, for at least ~10 hours, i.e., from 4 hours before performing baseline hemodynamic assessments until after the completion of the 6-hour study drug infusion;

- Have a body weight of at least 50kg (110 pounds), but not more than 125kg (275 pounds), and have a body mass index (BMI) <40kg/m2;

- Have adequate peripheral forearm vein access or an available central line port for administration of study drug;

- Be capable of understanding the nature of the trial; be willing and able to comply with the inpatient and outpatient study protocol requirements for the duration of the study (screening period, treatment period, and 30-day post-infusion follow-up period); and be willing to participate in the study, as documented by written informed consent.

Exclusion Criteria- - In order to be eligible for study participation, a patient MUST NOT:

- Have a heart rate <50 or >110 beats per minute (bpm) at baseline;

- Have a screening OR baseline systolic blood pressure (SBP) of >150mmHg or <100mmHg, if PCWP = 20mmHg, but <22mmHg OR <95mmHg, if PCWP = 22mmHg;

- Have tricuspid or pulmonary valve prosthesis or endocarditis, right heart mass, a history of pneumothorax or hemothorax, a bleeding diathesis that would preclude placement of a PAL, or a history of complications from previous pulmonary artery catheter placement, when a pulmonary artery catheter is to be placed solely for the purposes of monitoring the hemodynamic effects of the study drug; In this setting, patients with multiple intracardiac leads and/or left bundle branch block should have such elective pulmonary artery catheter placement performed under radiologic guidance by experienced personnel, e.g. in the cardiac catheterization laboratory. [Note: Other pertinent history, such as trauma, vascular injury or previous surgery should guide selection of the vessel for PAL placement.]

- Have a primary HF etiology attributable to either restrictive/obstructive cardiomyopathy, idiopathic hypertrophic cardiomyopathy (as defined by any wall thickness > 1.8cm) or uncorrected severe valvular disease as defined by AHA/ACC/ESC criteria;

- Have been treated with dopamine, dobutamine, enoximone, nesiritide, nitroglycerine or nitroprusside within 4 hours, or with levosimendan, amrinone or milrinone within 8 hours, prior to performing baseline hemodynamic assessments, or have an anticipated need to be treated with any of these agents before the completion of the 6-hour study drug infusion;

- Be receiving concomitant parenteral therapy with any antiarrhythmic drugs (oral therapy is allowed);

- Be in atrial fibrillation/flutter with an uncontrolled rate (=100bpm) at the time of randomization; [Note: Patients with a history of A-fib/flutter are eligible, if heart rate is controlled with a ventricular rate not exceeding 100bpm.]

- Have non-sustained ventricular tachycardia (NSVT) of 10 beats or more during any bedside monitoring within 2 hours prior to randomization, or have excessive premature ventricular contractions (PVCs) or complex multifocal ventricular ectopy exceeding 10 beats per minute on a 2-minute rhythm strip taken within 2 hours prior to randomization;

- Require, or be expected to require, any alteration of settings to an implantable cardioverter-defibrillator (ICD), single chamber or biventricular pacemaker, if applicable, from 2 hours before the intended start of the study drug infusion, until after the completion of the study drug infusion;

- Have a history of sudden cardiac death/resuscitation or other appropriate ICD firing within the past 1 year. (Inappropriate ICD firings are not exclusionary);

- Be hospitalized with acute coronary syndrome or acute myocardial infarction during the previous 90 days prior to randomization;

- Have a history of a cerebral vascular accident (CVA or stroke) or of a transient ischemic attack (TIA) within 6 months prior to randomization;

- Have a digoxin level above 1ng/ml (1.281nmol/L) within 8 hours before initiation of the study drug infusion;

- Have persistent abnormal serum electrolytes at baseline, as defined by: a Na+ concentration <130 or >145 mEq/L, or a K+ or Mg2+ concentration outside the normal range (according to the local laboratory); [Note: Any observed electrolyte abnormalities during screening or earlier should be corrected by electrolyte supplementation and within normal acceptable concentrations should be confirmed prior to dosing. Any serum electrolyte abnormalities with associated clinical instability within 8 hours before initiation of the study drug infusion is exclusionary.]

- Have an ALT or AST >3 times the upper normal limit or a hemoglobin <10g/dl (100g/L) within 8 hours before initiation of the study drug infusion;

- Have a serum creatinine >2.5mg/dl (221µmol/L) or severe renal insufficiency [based on any standard limit and equation employed by the local lab, such as a GFR < 30mL/min/1.73m2 according to the Modification of Diet in Renal Disease (MDRD) equation] within 8 hours before initiation of the study drug infusion;

- Have taken an oral phosphodiesterase type 5 inhibitor (PDE5) inhibitor within 96 hours before initiation of the study drug infusion;

- If female, be pregnant or of child-bearing potential (i.e., female patients must be post-menopausal or surgically sterilized);

- Be receiving a drug which is expected to possess a potential for a clinically significant pharmacokinetic interaction with CXL-1427, as defined in the CXL-1427 Investigator's Brochure;

- Be the recipient of a myocardial restraint device or flap;

- Have an anticipated survival of less than 90 days, for any reason;

- Have received an investigational drug, device or biologic product within 30 days (or if longer, 5 half-lives for a drug or biologic agent) prior to randomization, or be planning to receive an investigational agent at any time throughout the full duration of the study until at least 30 days after discontinuation of study drug;

- Have any other clinically significant laboratory abnormality, medical condition or social circumstance that, in the investigator's opinion, makes it inappropriate for the patient to participate in this clinical trial.

Study Design


Intervention

Drug:
CXL-1427

Placebo


Locations

Country Name City State
Germany Cardioxyl Study Site Bad Neuheim
Germany Cardioxyl Study Site Cologne
Germany Cardioxyl Study Site Frankfurt
Germany Cardioxyl Study Site Gottingen
Germany Cardioxyl Study Site Greifswald
Germany Cardioxyl Study Site Kiel
Germany Cardioxyl Study Site Regensberg
Jordan Cardioxyl Study Site Amman
Jordan Cardioxyl Study Site Irbid
Poland Cardioxyl Study Site Lodz
Poland Cardioxyl Study SIte Warsaw
Poland Cardioxyl Study Site Warsaw
Poland Cardioxyl Study Site Wroclaw
Russian Federation Cardioxyl Study Site Kemerovo
Russian Federation Cardioxyl Study Site Moscow
Russian Federation Cardioxyl Study Site Moscow
Russian Federation Cardioxyl Study Site Moscow
Russian Federation Cardioxyl Study Site Moscow
Russian Federation Cardioxyl Study Site St. Petersburg
Russian Federation Cardioxyl Study Site St. Petersburg
Russian Federation Cardioxyl Study Site Tomsk
United States Cardioxyl Study Site Baltimore Maryland
United States Cardioxyl Study Site Chapel Hill North Carolina
United States Cardioxyl Study Site Charleston South Carolina
United States Cardioxyl Study Site Cincinnati Ohio
United States Cardioxyl Study Site Columbus Ohio
United States Cardioxyl Study Site Detroit Michigan
United States Cardioxyl Study Site Gainesville Florida
United States Cardioxyl Study Site Jacksonville Florida
United States Cardioxyl Study Site Jacksonville Florida
United States Cardioxyl Study Site Macon Georgia
United States Cardioxyl Study Site Nashville Tennessee
United States Cardioxyl Study Site Newark New Jersey
United States Cardioxyl Study Site Richmond Virginia
United States Cardioxyl Study Site Salt Lake City Utah

Sponsors (2)

Lead Sponsor Collaborator
Bristol-Myers Squibb Cardioxyl Pharmaceuticals, Inc

Countries where clinical trial is conducted

United States,  Germany,  Jordan,  Poland,  Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Treatment-Emergent Adverse Events A treatment-emergent adverse event (TEAE) was defined as an AE with onset after the start of the study drug infusion at Hour 00:00 through 30 days after the stop of the study drug infusion. All TEAEs and pertinent subsets of TEAEs (e.g., TEAEs with onset during the infusion of study drug, serious TEAEs, etc.) were summarized by system organ class (SOC), preferred term (PT) and treatment group 30 days following the initiation of treatment
Primary Mean Time Averaged Change From Baseline in Adjudicated Pulmonary Capillary Wedge Pressure (PCWP) During Infusion The effect of CXL-1427 on PCWP is presented as the mean time-averaged change from baseline over the course of infusion of CXL-1427 or placebo in adjudicated pulmonary capillary wedge pressure (PCWP) on a modified intent-to-treat population Baseline, Hour 2, Hour 4, Hour 6, Hour 8 post infusion
Primary Mean Time-Averaged Change From Baseline in Adjudicated Pulmonary Artery Diastolic Pressure (PAD) During the Infusion Pulmonary artery diastolic pressure (PAD) was measured by an indwelling PA catheter. Pulmonary artery diastolic pressure (PAD) approximates pulmonary capillary wedge pressure in normal individuals. The effects of CXL-1427 on time-averaged PAD during the course of the infusion are presented. Baseline, Hour 2, Hour 4, Hour 6, Hour 8 post infusion initiation
Primary Mean Time-Averaged Percent Change From Baseline in Cardiac Index (Fick) Cardiac index is a measure of cardiac function, relating the cardiac output from the left ventricle in one minute to body surface area. It is calculated using the Fick principle, using oxygen consumption measured with a metabolic cart, hemoglobin levels, and the difference between arterial and superior vena cava oxygen saturation measured by co-oximetry. Cardiac index as calculated by the Fick method was performed using an assumed oxygen consumption value of 125 ml/min per m2 of body surface area. i.e., an assumed Fick method. Baseline, Hour 2, Hour 4, Hour 6, Hour 8 post infusion initiation
Secondary Mean Time-Averaged Change From Baseline in Adjudicated Pulmonary Artery Systolic Pressure (PAS) During the Infusion Pulmonary artery systolic pressure (PAS) was measured by an indwelling PA catheter. The effects of CXL-1427 on time-averaged PAS during the course of the infusion are presented Baseline, Hour 2, Hour 4, Hour 6, Hour 8 post infusion initiation
Secondary Mean Time-Averaged Change From Baseline in Adjudicated Right Atrial Pressure (RAP) During the Infusion The effects of CXL-1427 on time-averaged RAP during the course of the infusion are presented Baseline, Hour 2, Hour 4, Hour 6, Hour 8 post infusion initiation
Secondary Mean Time-Averaged Change From Baseline in Mean Arterial Blood Pressure (MAP) During the Infusion Mean arterial pressure during infusion of CXL-1427 or placebo on a modified intent-to-treat population is presented Baseline, Hour 24 after infusion, Follow-up visit 1
Secondary Mean Time-Averaged Change From Baseline in Systolic Blood Pressure (SBP) During the Infusion Mean Time-Averaged Change from Baseline in Systolic Blood Pressure during infusion of CXL-1427 or placebo on a modified intent-to-treat population is presented Baseline, Hour 24 after infusion, Follow-up visit 1
Secondary Mean Time-Averaged Change From Baseline in Diastolic Blood Pressure (DBP) During the Infusion Mean Time-Averaged Change from Baseline in Diastolic Blood Pressure during infusion of CXL-1427 or placebo on a modified intent-to-treat population is presented Baseline, Hour 24 after infusion, Follow-up visit 1
Secondary Mean Time-Averaged Change From Baseline in Heart Rate (HR) During the Infusion Mean Time-Averaged Change from Baseline in Heart Rate during infusion of CXL-1427 or placebo on a modified intent-to-treat population is presented Baseline, Hour 24 after infusion, Follow-up visit 1
See also
  Status Clinical Trial Phase
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05654272 - Development of CIRC Technologies
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy